权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Improved Whole-Brain Spectroscopic MRI for Radiation Treatment Planning

改进的全脑光谱 MRI 用于放射治疗计划

基本信息

批准号：
9981743
负责人：
Lee Cooper
金额：
$ 77.5万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-22 至 2021-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9981743
关键词：
Achievement Adjuvant Adopted Adoption Algorithms Area Brain Brain Neoplasms Brain imaging Cells Cerebrum Choline Clinical Clinical Management Clinical Research Collaborations Computer software Data Decision Making Deltastab Detection Development Disease Dose Engineering Enhancing Lesion Enrollment Excision Frequencies Future Genomics Glioblastoma Glioma Goals Head Image Infiltration Institution Knowledge Lead Left Lipids Magnetic Resonance Imaging Malignant neoplasm of brain Maps Methods Morbidity - disease rate Motion Multi-site clinical study N-acetylaspartate Nature Newly Diagnosed Outcome Patients Pattern Performance Protocols documentation Radiation Radiation Dose Unit Radiation therapy Recurrence Reproducibility Research Resolution Signal Transduction Site Software Tools Technology Testing Time Tissues Tumor Volume Update Visualization software base brain volume central database chemotherapy clinical imaging cloud based data management data visualization design effective therapy high risk imaging modality improved magnetic field mortality multiple datasets reconstruction software systems spectroscopic imaging standard of care subcutaneous success temozolomide tool treatment planning tumor web based interface

项目摘要

Identifying the extent of glioma tumor margins for radiation treatment planning remains a challenging task due to the infiltrative nature of these tumors and limitations in current standard imaging methods. Multiple studies including our own have demonstrated that MR spectroscopic imaging, or spectroscopic MRI (sMRI), can detect areas of infiltrating tumor with a high degree of sensitivity, and could be an essential tool in treating areas that lead to early recurrence. sMRI enables the identification of infiltrating cells that are marked by increased Choline/N-Acetylaspartate ratios, including regions that are not detectable by standard MRI and normally left untreated. Therefore, sMRI shows considerable promise for improving the efficacy of radiation treatment and significantly delay recurrence. However, technological improvements are needed before sMRI can be broadly adopted for clinical use. This study will achieve this goal by leveraging diverse areas of expertise at four research sites to engineer and validate technological improvements needed to improve sMRI acquisition, analysis, and clinical integration. These improvements will include new magnet shimming technology to increase the spatial coverage of sMRI to whole-brain volumes; updated rapid and motion-robust sMRI method that incorporates compressed sensing to both increase spatial resolution and decrease acquisition times; and new processing, display, and analysis methods that will present metabolite maps in an efficient manner with a clinician-friendly web-based interface that enables integration with radiation treatment planning software systems. The value and efficacy of the technological developments will be validated in a clinical study at the participating sites that will incorporate sMRI into RT planning for glioblastoma, using an escalated dose for regions of significantly increased Cho/NAA. The completion of this study will provide robust sMRI acquisition methods and software tools that will be suitable for clinical use.

为放射治疗计划确定胶质瘤肿瘤边缘的范围仍然是一项具有挑战性的任务这些肿瘤的浸润性和目前标准成像方法的局限性。多项研究包括我们自己的已经证明了磁共振光谱成像，或光谱核磁共振(SMRI)可以检测到具有高度敏感性的浸润性肿瘤区域，可作为治疗以下区域的必要工具导致早期复发。SMRI能够识别标记为增加的浸润性细胞胆碱/N-乙酰天冬氨酸比率，包括标准MRI无法检测到的和正常左侧的区域未经治疗。因此，sMRI显示出相当大的希望来提高放射治疗的疗效和显著延缓复发。然而，在sMRI能够广泛应用之前，还需要改进技术。被采纳用于临床。这项研究将通过利用四个不同领域的专业知识来实现这一目标研究站点，以设计和验证改善sMRI获取所需的技术改进，分析和临床整合。这些改进将包括新的磁体垫片技术，以增加sMRI对全脑体积的空间覆盖；更新快速和运动稳健的sMRI方法它结合了压缩传感以提高空间分辨率和减少采集时间；新的处理、显示和分析方法，将以高效的方式提供代谢物图谱临床医生友好的基于Web的界面，支持与放射治疗计划软件集成系统。技术发展的价值和效果将在一项临床研究中得到验证参与地点将把sMRI纳入胶质母细胞瘤的RT计划，使用逐步增加的剂量 Cho/NAA显著升高的区域。这项研究的完成将提供强大的smri获取。适合临床使用的方法和软件工具。